Drug therapy: dose‐response relationship of oral mesalazine in inflammatory bowel disease [PDF]
Mesalazine is widely used in the treatment of inflammatory bowel disease. Little is known about the doseresponse relationship and about possible dose related side effects. In ulcerative colitis higher dosages of mesalazine (3 g) are more effective in maintaining a remission than lower dosages (1.5 g).
Chris J. J. Mulder, S. J. Van Den Hazel
openaire +4 more sources
Design considerations and analysis planning of a phase 2a proof of concept study in rheumatoid arthritis in the presence of possible non-monotonicity [PDF]
BACKGROUND: It is important to quantify the dose response for a drug in phase 2a clinical trials so the optimal doses can then be selected for subsequent late phase trials.
AE Raftery+17 more
core +4 more sources
drexplorer: A tool to explore dose–response relationships and drug–drug interactions [PDF]
AbstractMotivation: Nonlinear dose–response models are primary tools for estimating the potency [e.g. half-maximum inhibitory concentration (IC) known as IC50] of anti-cancer drugs. We present drexplorer software, which enables biologists to evaluate replicate reproducibility, detect outlier data points, fit different models, select the best model ...
Lauren Averett Byers+8 more
openaire +3 more sources
Dose-Response Relationship between Antimicrobial Drugs and Livestock-Associated MRSA in Pig Farming1 [PDF]
The farming community can be a vehicle for introduction of livestock-associated methicillin-resistant Staphylococcus aureus (LA-MRSA) in hospitals. During 2011-2013, an 18-month longitudinal study aimed at reducing the prevalence of LA-MRSA was conducted on 36 pig farms in the Netherlands.
Dorado-García, Alejandro+6 more
openaire +6 more sources
Pharmacokinetic-Pharmacodynamic and Dose-Response Relationships of Antituberculosis Drugs: Recommendations and Standards for Industry and Academia [PDF]
Antimicrobial pharmacokinetic-pharmacodynamic (PK/PD) science is vital to early antibiotic drug development to enable more efficient dose-effect study designs, identification of doses that may suppress drug resistance and choice of susceptibility breakpoints.
Santiago Ferrer-Bazaga+2 more
openaire +4 more sources
Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma : results from two phase 3, randomised, double-blind, placebo-controlled trials [PDF]
BACKGROUND: Reslizumab 3 mg/kg administered intravenously is approved for the treatment of severe eosinophilic asthma. We assessed the safety and efficacy of subcutaneous reslizumab 110 mg in two trials in patients with uncontrolled severe asthma and ...
Adir, Yochai+13 more
core +1 more source
The dose-response relationship for memory impairment by anticholinergic drugs
Twelve stabilized chronic schizophrenic outpatients receiving maintenance treatment with fluphenazine decanoate plus anticholinergic antiparkinsonian drugs underwent two challenge sessions receiving, in random sequence and double-blind, injections of either benztropine or glycopyrrolate (a peripherally active anticholinergic agent that penetrates the ...
Joseph P. McEvoy+3 more
openaire +3 more sources
Model Selection versus Model Averaging in Dose Finding Studies [PDF]
Phase II dose finding studies in clinical drug development are typically conducted to adequately characterize the dose response relationship of a new drug.
Bornkamp, Björn+3 more
core +2 more sources
Measurement and models accounting for cell death capture hidden variation in compound response. [PDF]
Cancer cell sensitivity or resistance is almost universally quantified through a direct or surrogate measure of cell number. However, compound responses can occur through many distinct phenotypic outcomes, including changes in cell growth, apoptosis, and
Bae, Song Yi+5 more
core +1 more source
Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. [PDF]
In part A of this study, patients were randomised to cohorts receiving darbepoetin alfa at doses of 0.5 to 8.0 m.c.g x kg(-1) x wk(-1) or to a control group receiving epoetin alfa at an initial dose of 150 U x kg(-1) three times weekly.
Armstrong, S+10 more
core +2 more sources